Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy
Authors:
- Nai-Hsuan ChienNCNai-Hsuan Chien
- Yen-Tsung HuangYHYen-Tsung Huang
- Chun-Ying WuCWChun-Ying Wu
- Chi-Yang ChangCCChi-Yang Chang
- Ming-Shiang WuMWMing-Shiang Wu
- Jia-Horng KaoJKJia-Horng Kao
- Lein-Ray MoLMLein-Ray Mo
- Chi-Ming TaiCTChi-Ming Tai
- Chih-Wen LinCLChih-Wen Lin
- Tzeng-Huey YangTYTzeng-Huey Yang
- Jaw-Town LinJLJaw-Town Lin
- Yao-Chun HsuYHYao-Chun Hsu
Open Access
- 8 December 2017
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 17 (1) , 1-7
Abstract
The serum gradient of hepatitis B surface antigen (HBsAg) varies over time after cessation of nucleos(t)ide analog (NA) treatment in patients with chronic hepatitis B (CHB). The association between the time-varying HBsAg serum gradient and risk of relapse has not been elucidated. This multicenter cohort study prospectively enrolled CHB patients who discontinued 3 year-NA treatment. Eligible patients were serologically negative for HBeAg and viral DNA at NA cessation. The participants (n = 140) were followed every 3 months through HBsAg quantification. Virological and clinical relapses were defined as viral DNA levels >2000 IU/mL and alanine aminotransferase (ALT) levels >80 U/mL, respectively. The association of time-varying HBsAg levels with relapses was assessed through a time-dependent Cox analysis. During a median follow-up of 19.9 (interquartile range [IQR], 10.6–25.3) months, virological and clinical relapses occurred in 94 and 49 patients, with a 2-year cumulative incidence of 79.2% (95% confidence interval [CI], 70.9%–86.4%) and 42.9% (95% CI, 34.1%–52.8%), respectively. The serum level of HBsAg was associated with virological (P < 0.001) and clinical (P = 0.01) relapses in a dose–response manner, with adjusted hazard ratios of 2.10 (95% CI, 1.45–3.04) and 2.32 (95% CI, 1.28–4.21). Among the patients (n = 19) whose HBsAg levels ever dropped below 10 IU/mL, only one and three patients subsequently developed clinical and virological relapses. The serum gradient of HBsAg measured throughout the off-therapy observation is associated with the subsequent occurrence of virological and clinical relapses in CHB patients who discontinue NA treatment.Keywords
Funding Information
- Cathay General Hospital and Fu-Jen University (104-GGH-FJU-11)
- E-Da Hospital (EDAHP105019)
- Taipei Pathology Institutes (TIP104-2)
This publication has 33 references indexed in Scilit:
- Significant reduction in end‐stage liver diseases burden through the national viral hepatitis therapy program in TaiwanHepatology, 2014
- Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort StudyGastroenterology, 2014
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infectionJournal of Hepatology, 2012
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateHepatology International, 2012
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- Recent advances in the treatment of chronic hepatitis BExpert Opinion on Pharmacotherapy, 2011
- Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡Hepatology, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Hepatitis B virus infectionThe Lancet, 2009